Biotechnology and government experts from the America and Britain will gather on Nov. 10 for a “US Innovation Meets UK Opportunity.”

The event is a business seminar on expanding biotechnology business to the United Kingdom. The one-day event runs in conjunction with the Southeast BIO Investor Conference (SEBIO) in Pinehurst, NC.

UK Trade & Investment, the North of England Inward Investment Agency and law firm Kilpatrick Stockton are the hosts. The event is designed to bring together local biotechnology companies that have expanded to the UK, government officials involved in technology transfer and legal and venture capital representatives to discuss licensing, regulatory issues and partnering opportunities necessary for any company interested in expanding.

Panelists include Tom O’Toole, deputy director of technology transfer from the Centers for Disease Control. O’Toole will be discussing tech transfer successes with both US and UK companies and universities, as well as progress made in the diagnosis of West Nile and other infectious diseases.

Also taking part will be David Rhodes, head of business development at the UK Centre for Applied Microbiology and Research, which conducted a majority of the testing of last year’s anthrax letters and has one of only two licensed anthrax vaccines in the world. Rhodes will be discussing the different types of tech transfer, how to find partners to help take technology forward and find venture capital for mid-stage companies.

Other panelists include Stephen Porter, CEO of Virtual Drug Development Inc. of Brentwood, TN, that recently opened an office in Northern Ireland; Bruce Lowrey, CFO of Scynexis in RTP, with offices in Cambridge, England; and Mike Steele, director of Atlanta-based Serologicals, which has offices in Scotland and the UK.